Tag: Prescription Review Program

Saskatchewan Nurse Practitioners (NPs) are authorized in accordance with provincial and federal legislation to prescribe and/or dispense drugs listed in Schedules I, II and III of The Drug Schedules Regulations, 1997, as amended from time to time. The CRNS participates in the Prescription Review Program (PRP) established in Saskatchewan, and all practicing NPs engage in a reflective practice assessment specific to PRP from time to time. The primary objective of the CRNS’s PRP is ensuring patient safety through safe prescribing practices. 

The Prescription Review Program quality initiative (QI) helps to confirm that the NP’s prescribing practice is aligned with the relevant standards and guidelines. Many NPs find the opportunity to reflect on their prescribing practice as a valuable investment. This program will be launching this fall and you may be randomly chosen to participate. More information can be accessed here (add link to webpage).

Questions can be directed to the PRP Nursing Advisor at prp@crns.ca.

Effective March 31, 2022, tramadol will be removed from the Prescription Drug List (PDL) and listed in Schedule 1 of the Controlled Drugs and Substances Act (CDSA). Tramadol will also be listed as item 19 in the Schedule of the Narcotic Control Regulations (NCR). This means that tramadol will be subject to all the regulatory requirements set out in the CDSA and NCR. The rational to change the listing is to reduce risks to human health, and to facilitate the detection and prevention of diversion of tramadol.

For a full explanation, including impact to practice, please visit:

https://gazette.gc.ca/rp-pr/p2/2021/2021-03-31/html/sor-dors43-eng.html

If you have any question about your NP practice, please contact practicadvice@crns.ca.  If you have any questions about prescribing controlled drugs and substances or the CRNS

Prescription Review Program, please contact prp@crns.ca